• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Index insights
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Israel
  • Rise of obesity
  • Radiopharmaceuticals
  • Biosimilars
  • Aging
  • IVDs on the rise
  • Coronavirus
  • Artificial intelligence

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Newsletters » BioWorld

BioWorld

May 25, 2012

View Archived Issues

PDUFA Passes the Senate, Awaits Debate on House Floor

WASHINGTON – Biopharma has cause to celebrate as PDUFA V rolled through the Senate Thursday with little in the way of fireworks. The FDA Innovation and Safety Act (FDASIA), S. 3187, passed the Senate 96-1 after a full day of debate on various amendments. Read More

AdComm Offers Split Opinion in Vyndaqel Single Study

Members of the FDA's Peripheral and Central Nervous System (PCNS) Drugs Advisory Committee delivered a split opinion Thursday on the use of a single study by sponsor Pfizer Inc., which is seeking approval for Vyndaqel (tafamidis meglumine) in the orphan indication transthyretin (TTR) familial amyloid polyneuropathy (FAP). Read More

Following Phase IIb Miss, MediciNova Will Press Onward

A Phase IIb trial intended to show the benefit of MediciNova Inc.'s asthma candidate, MN-221, failed to meet its primary endpoint of improved forced expiratory volume in one second (FEV1) compared to placebo, sending the company's stock plummeting 43.3 percent Thursday. Read More

Possible Accelerated Approval Path 'EMERGE[s]' for CDX-011

Celldex Therapeutics Inc. is eyeing an accelerated approval pathway after preliminary Phase IIb data showed impressive response rates in three subsets of heavily pretreated breast cancer patients given glycoprotein NMB (GPNMB)-targeting antibody-drug conjugate CDX-011 (glembatumumab vedotin). Read More

Holiday Notice

BioWorld's offices will be closed Monday, May 28 in observance of the Memorial Day holiday in the U.S. Read More

Financings Roundup

• Catalyst Pharmaceutical Partners Inc., of Coral Gables, Fla., said it priced a public offering of 6 million units – each unit comprising one share of common stock and a warrant to purchase up to one share – at 80 cents apiece. Read More

Other News To Note

• Gilead Sciences Inc., of Foster City, Calif., said the European Medicines Agency validated its marketing authorization application (MAA) for cobicistat, submitted on April 26. Cobicistat is Gilead's pharmaco-enhancing agent to increase blood levels of certain commercially available protease inhibitors, including atazanavir (Reyataz, Bristol-Myers Squibb Co.) and darunavir (Prezista, Tibotec Pharmaceuticals), to enable once-daily dosing. Read More

Stock Movers

Read More

Clinic Roundup

• Bionomics Ltd., of Adelaide, Australia, said it launched a Phase I/II trial of BNC105 in women with ovarian cancer. Up to 134 patients are expected to be enrolled in the study, which is designed to test the vascular-disrupting agent in combination with current standard therapies carboplatin and gemcitabine. Read More

Pharma: Clinic Roundup

• Boehringer Ingelheim Pharmaceuticals Inc., of Ridgefield, Conn., and Eli Lilly and Co., of Indianapolis, reported Phase III results for Tradjenta (linagliptin) 5 mg once-daily, which showed significant hemoglobin A1c reduction of 0.88 percent compared with 0.24 percent in the placebo group at 24 weeks. Read More

Pharma: Other News To Note

• Mylan Inc., of Pittsburgh, said its UK and Italy-based subsidiaries launched ibandronic acid film coated tablets, the generic version of Basel, Switzerland-based Roche AG's Bonviva tablets, in osteoporosis. Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 20, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for June 18, 2025.
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for June 17, 2025
  • Red blood cells in an artery with cholesterol

    In two phase IIIs, Merck’s PCSK9 inhibitor cuts cholesterol

    BioWorld
    In two phase III studies, Merck & Co. Inc.’s oral, once monthly proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor produced statistically significant...
  • Enflonsia

    Merck wins FDA approval in pediatric RSV and steps into CDC uncertainty

    BioWorld
    With the U.S. FDA’s approval of Enflonsia (clesrovimab) to prevent respiratory syncytial virus (RSV) infection lower respiratory tract disease in newborns and...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe